ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

Abstract excerpt

The met proto-oncogene is functionally linked with tumorigenesis and metastatic progression. Validation of the receptor tyrosine kinase c-Met as a selective anticancer target has awaited the emergence of selective c-Met inhibitors. Herein, we report ARQ 197 as the first non-ATP-competitive small molecule that selectively targets the c-Met receptor tyrosine kinase. Exposure to ARQ 197 resulted in the inhibition of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Liver physiology and pathology
• Share to Pancreatic and Hepatic Oncology Research
• Share to PI3K/AKT/mTOR signaling in cancer